Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 3Lung Neoplasms 2Leukemia 2Urogenital Neoplasms 1Solid Tumors 1Small Cell Lung Carcinoma 1Recurrence 1Recovery 1Ovarian Neoplasms 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Keratosis, Actinic 1Genital Neoplasms, Male 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

padeliporfin 5Pluvicto 2Paclitaxel 2Abiraterone Acetate 2sipuleucel-T 1rucaparib 1pembrolizumab 1palladium-bacteriopheophorbide 1onapristone 1olaparib 1niraparib 1luprolide acetate gel depot 1ixabepilone 1gallium 68 PSMA-11 1apalutamide 1abiraterone 1Therapeutics 1Suspensions 1Radiotherapy 1Radiation Dose Hypofractionation 1Powders 1Nivolumab 1Leuprolide 1Ipilimumab 1Imatinib Mesylate 1Gemcitabine 1EPI-506 1Cisplatin 1Chemical Fractionation 1Biopsy, Needle 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Genital Neoplasms, Male × Powders × Clear all
NCT04221828 2022-03-29

Trial of NanoPac Focal Therapy for Prostate Cancer

NanOlogy, LLC

Phase 2 Terminated
1 enrolled 5 charts
Genitourinary

Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡